Table 3.
Total cost, total effectiveness, and incremental cost-effectiveness for 1 year of testing (Dec 1, 2018, to Nov 30, 2019)
| Total cost (95% UI)* | Number of patients tested (95% UI)* | Number of patients diagnosed with tuberculosis within 6 months (95% UI)* | Number of patients initiating treatment in 14 days (95% UI)* | Cost per patient (95% UI)* |
Incremental cost-effectiveness ratio |
||
|---|---|---|---|---|---|---|---|
| Cost per additional tuberculosis diagnosis (95% UI)* | Cost per additional treatment initiation in 14 days (95% UI)* | ||||||
| Centralised | $37 123 (27 493–53 343) | 3871 (2397–5044) | 250 (145–347) | 179 (102–247) | $9·59 (9·43–12·55) | .. | .. |
| Decentralised | $83 816 (69 585–111 758) | 4135 (2540–5426) | 285 (165–395) | 247 (143–344) | $20·27 (18·90–29·29) | .. | .. |
| Difference | $46 693 (40 364–61 646) | 264 (126–417) | 35 (8–69) | 68 (37–108) | $10·67 (8·78–17·04) | $1332 (763–5558) | $687 (501–1207) |
UI=uncertainty interval. XPEL-TB=Xpert Performance Evaluation for Linkage to Tuberculosis Care.
*
The point estimates are based on empiric observations from the XPEL-TB trial for a 1-year period from Dec 1, 2018, to Nov 30, 2019. 95% uncertainty ranges were calculated using a Monte Carlo simulation (1000 iterations), with parameter inputs based on the variability in cost-effectiveness observed in the XPEL-TB trial. All costs presented in 2019 US$.